Mer­ck’s bad day: $310M for Not­Petya, fran­chise drugs take a hit and now the EMA push­es back on Keytru­da

Mer­ck $MRK took a se­ries of hits on Fri­day, capped by news af­ter the mar­ket closed that its Eu­ro­pean ap­pli­ca­tion for its Keytru­da/chemo com­bo for front­line non-small cell lung can­cer was be­ing scrapped in the face of a push­back from the EMA.

In the morn­ing, rolling out its Q3 num­bers, Mer­ck was forced to con­cede that the Not­Petya cy­ber at­tack had cost the com­pa­ny $135 mil­lion in lost sales along with $175 mil­lion in re­lat­ed costs while forc­ing them to bor­row $240 mil­lion worth of Gar­dasil from fed­er­al stock­piles. That ex­tra $310 mil­lion in costs will be re­peat­ed in Q4, Mer­ck not­ed in their quar­ter­ly call, as over­all dam­ages roll up to the $1 bil­lion mark.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER